Original Article

You have full text access to this OnlineOpen article

Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas

  1. Simona Grozinsky-Glasberg MD1,2,†,*,
  2. Dganit Barak MRS3,
  3. Merav Fraenkel MD3,
  4. Martin A. Walter MD4,
  5. Jan Müeller-Brand MD4,
  6. Joseph Eckstein MD5,
  7. Liat Applebaum MD6,
  8. Ilan Shimon MD1,2,
  9. David J. Gross MD3

Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25646

Issue

Cancer

Cancer

Volume 117, Issue 7, pages 1377–1385, 1 April 2011

Additional Information

How to Cite

Grozinsky-Glasberg, S., Barak, D., Fraenkel, M., Walter, M. A., Müeller-Brand, J., Eckstein, J., Applebaum, L., Shimon, I. and Gross, D. J. (2011), Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer, 117: 1377–1385. doi: 10.1002/cncr.25646

Author Information

  1. 1

    Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Tel Aviv, Israel

  2. 2

    Sackler Faculty of Medicine, Tel Aviv, Israel

  3. 3

    Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

  4. 4

    Institute of Nuclear Medicine, University Hospital, Basel, Switzerland

  5. 5

    Imaging Department, Beilinson Hospital, Rabin Medical Center, Tel Aviv, Israel

  6. 6

    Imaging Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

  1. †

    Fax: (011) 972-3-9211403

*Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, 49100 Israel

Publication History

  1. Issue published online: 18 MAR 2011
  2. Article first published online: 8 NOV 2010
  3. Manuscript Accepted: 16 AUG 2010
  4. Manuscript Revised: 30 JUL 2010
  5. Manuscript Received: 18 JUN 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (357K)

REFERENCES

  • 1
    Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006; 84: 173-182.
  • 2
    Rindi G, Kloppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology. 2004; 80( suppl 1): 12-15.
  • 3
    Mignon M, Cadiot G. Natural history of gastrinoma: lessons from the past. Ital J Gastroenterol Hepatol. 1999; 31( suppl 2): S98-S103.
  • 4
    Li ML, Norton JA. Gastrinoma. Curr Treat Options Oncol 2001; 2: 337-346.
  • 5
    Howard TJ, Zinner MJ, Stabile BE, Passaro EJr. Gastrinoma excision for cure. A prospective analysis. Ann Surg. 1990; 211: 9-14.
  • 6
    Landor JH. Control of the Zollinger-Ellison syndrome by excision of primary and metastatic tumor. Am J Surg. 1984; 147: 406-409.
  • 7
    Stabile BE, Morrow DJ, Passaro EJr. The gastrinoma triangle: operative implications. Am J Surg. 1984; 147: 25-31.
  • 8
    Ellison EC, Sparks J, Verducci JS, et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg. 2006; 202: 897-905.
  • 9
    Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999; 17: 615-630.
  • 10
    Pellicano R, De Angelis C, Resegotti A, Rizzetto M. Zollinger-Ellison syndrome in 2006: concepts from a clinical point of view. Panminerva Med. 2006; 48: 33-40.
  • 11
    DeLellis RA, Eng C, Heitz PU, Lloyd RV. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC; 2009.
  • 12
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
  • 13
    Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001; 12: 941-945.
  • 14
    Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28: 1319-1325.
  • 15
    Iten F, Muller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007; 13: 6696-6702.
  • 16
    Iten F, Muller B, Schindler C, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009; 115: 2052-2062.
    Direct Link:
  • 17
    Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20: 716-731.
  • 18
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
  • 19
    Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449: 395-401.
  • 20
    Arnold R, Rinke A, Schmidt C, Hofbauer L. Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol. 2005; 19: 649-656.
  • 21
    Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992; 112: 1024-1031.
  • 22
    Plockinger U, Wiedenmann B. Endocrine tumours of the gastrointestinal tract. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005; 19: 553-576.
  • 23
    Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002; 94: 331-343.
    Direct Link:
  • 24
    Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005; 46( suppl 1): 67S-75S.
  • 25
    Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23: 2754-2762.
  • 26
    de Jong M, Breeman WA, Bernard BF, et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med. 2001; 42: 1841-1846.
  • 27
    Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006; 26: 703-707.
  • 28
    Waldherr C, Haldemann A, Maecke HR, Crazzolara A, Mueller-Brand J. Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. Clin Oncol (R Coll Radiol). 2000; 12: 121-123.
  • 29
    Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002; 43: 610-616.
  • 30
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005; 46( suppl 1): 62S-66S.
  • 31
    Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996; 32A: 1135-1141.
  • 32
    de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002; 32: 133-140.
  • 33
    Valkema R, de Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002; 32: 110-122.
  • 34
    van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010; 51: 383-390.
  • 35
    Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002; 32: 123-132.
  • 36
    Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008; 35: 1847-1856.
  • 37
    Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005; 46: 1310-1316.
  • 38
    Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003; 30: 417-422.
View Full Article (HTML) Get PDF (357K)